A study conducted by researchers at Mount Sinai Health System analyzed the antibody responses of 30,082 individuals infected with SARS-CoV-2. The results showed that most individuals with mild-to-moderate COVID-19 developed robust immunoglobulin G (IgG) antibodies against the viral spike protein. These antibodies remained stable for at least five months and were strongly correlated with neutralizing activity against SARS-CoV-2. Over 90% of seroconverters produced detectable neutralizing antibodies, with titers remaining relatively stable for several months after infection. The study used an enzyme-linked immunosorbent assay (ELISA) to measure antibody titers, which showed high sensitivity and specificity. Neutralization titers were found to correlate strongly with ELISA titers, indicating that antibodies produced in response to SARS-CoV-2 can neutralize the virus. The study also found that antibody titers declined slowly over time, with a slight drop observed from the first to the third time point. However, neutralizing antibody titers remained stable, with a good correlation observed even at the 148-day mark. The study also found that individuals who had initially low antibody titers could lose reactivity over time, suggesting that very low initial titers may not persist. The researchers concluded that the antibody response to SARS-CoV-2 is robust and long-lasting, with neutralizing antibodies providing protection against reinfection. The study highlights the importance of understanding the longevity and functionality of the antibody response to inform serosurveys and vaccine development. The findings suggest that individuals who have recovered from mild COVID-19 may have a protective immune response, although conclusive evidence of protection against reinfection is still lacking. The study underscores the need for further research to establish a correlate of protection for SARS-CoV-2 infection.A study conducted by researchers at Mount Sinai Health System analyzed the antibody responses of 30,082 individuals infected with SARS-CoV-2. The results showed that most individuals with mild-to-moderate COVID-19 developed robust immunoglobulin G (IgG) antibodies against the viral spike protein. These antibodies remained stable for at least five months and were strongly correlated with neutralizing activity against SARS-CoV-2. Over 90% of seroconverters produced detectable neutralizing antibodies, with titers remaining relatively stable for several months after infection. The study used an enzyme-linked immunosorbent assay (ELISA) to measure antibody titers, which showed high sensitivity and specificity. Neutralization titers were found to correlate strongly with ELISA titers, indicating that antibodies produced in response to SARS-CoV-2 can neutralize the virus. The study also found that antibody titers declined slowly over time, with a slight drop observed from the first to the third time point. However, neutralizing antibody titers remained stable, with a good correlation observed even at the 148-day mark. The study also found that individuals who had initially low antibody titers could lose reactivity over time, suggesting that very low initial titers may not persist. The researchers concluded that the antibody response to SARS-CoV-2 is robust and long-lasting, with neutralizing antibodies providing protection against reinfection. The study highlights the importance of understanding the longevity and functionality of the antibody response to inform serosurveys and vaccine development. The findings suggest that individuals who have recovered from mild COVID-19 may have a protective immune response, although conclusive evidence of protection against reinfection is still lacking. The study underscores the need for further research to establish a correlate of protection for SARS-CoV-2 infection.